Literature DB >> 2171882

Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis.

N Keicho1, K Kitamura, F Takaku, H Yotsumoto.   

Abstract

We investigated the clinical value of measuring serum concentrations of soluble IL-2R in monitoring sarcoidosis. Serum concentrations of soluble IL-2R were measured in 70 patients with sarcoidosis. The mean value for active untreated sarcoidosis was 1,143 +/- 509 U/ml, while the normal range in 97 healthy control subjects was 80 to 300 U/ml. The mean value for active untreated sarcoidosis was significantly higher than that for dormant disease (353 +/- 183 U/ml) or that for corticosteroid-treated patients (380 +/- 151 U/ml). Serial changes in serum soluble IL-2R level were studied in cases of spontaneous remission or in corticosteroid-treated patients; a good correlation was noted between the changes in serum level of soluble IL-2R and clinical status. A positive correlation was noted between serum concentration of soluble IL-2R and serum ACE activity. These data confirmed that measurement of serum concentration of soluble IL-2R could be used in monitoring the disease activity in sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2171882     DOI: 10.1378/chest.98.5.1125

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

1.  Biological role of the soluble interleukin-2 receptor in sarcoidosis.

Authors:  Remi M M Vanmaris; Ger T Rijkers
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  [Interferon-alfa induced reactivation of sarcoidosis in a patient with chronic hepatitis C].

Authors:  I Mederacke; K Wursthorn; H Ho; M P Manns; H Wedemeyer
Journal:  Internist (Berl)       Date:  2010-04       Impact factor: 0.743

3.  Serum markers of T cell activation in relapses of Wegener's granulomatosis.

Authors:  C A Stegeman; J W Tervaert; M G Huitema; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

4.  Serum and urine soluble interleukin-2 receptor in idiopathic nephrotic syndrome.

Authors:  G H Bock; J R Ongkingco; L T Patterson; J Ruley; L R Schroepfer; D L Nelson
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

5.  Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis.

Authors:  Hela-Felicitas Petereit; Dirk Reske; Hayrettin Tumani; Sven Jarius; F Markus Leweke; Dirk Woitalla; Hans-Walter Pfister; Andrea Rubbert
Journal:  J Neurol       Date:  2010-06-17       Impact factor: 4.849

6.  Serum soluble interleukin-2 receptor level is a predictive marker for EBUS-TBNA-based diagnosis of sarcoidosis.

Authors:  Jun Miyata; Takunori Ogawa; Yoichi Tagami; Takashi Sato; Mikie Nagayama; Toshiyuki Hirano; Naofumi Kameyama; Koichi Fukunaga; Akihiko Kawana; Takashi Inoue
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-03-15       Impact factor: 0.670

7.  Subcutaneous sarcoidosis: a clinical analysis of nine patients.

Authors:  Masaru Ando; Eishi Miyazaki; Yutaka Hatano; Suehiro Nishio; Chihiro Torigoe; Mari Yamasue; Yutaka Mukai; Shin-Ichi Nureki; Jun-Ichi Kadota
Journal:  Clin Rheumatol       Date:  2016-07-23       Impact factor: 2.980

8.  18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis.

Authors:  Ruth G Keijsers; Fred J Verzijlbergen; Wim J Oyen; Jules M van den Bosch; Henk J Ruven; Heleen van Velzen-Blad; Jan C Grutters
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-04       Impact factor: 9.236

Review 9.  Serum biomarkers in interstitial lung diseases.

Authors:  Argyris Tzouvelekis; George Kouliatsis; Stavros Anevlavis; Demosthenes Bouros
Journal:  Respir Res       Date:  2005-07-21

10.  Activation of mucosal-associated invariant T cells in the lungs of sarcoidosis patients.

Authors:  Hisayo Matsuyama; Takuma Isshiki; Asako Chiba; Tetsuo Yamaguchi; Goh Murayama; Yoshikiyo Akasaka; Yoshinobu Eishi; Susumu Sakamoto; Sakae Homma; Sachiko Miyake
Journal:  Sci Rep       Date:  2019-09-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.